Tufts-New England Medical Center (Tufts-NEMC) has served as a main institution for the Eastern Cooperative Oncology Group for 40 years. During that time, the network has enrolled over 6500 patients on NCI sponsored cancer clinical trials and it has made many scientific and administrative contributions to ECOG. The development of a large and growing network throughout New England, combined with contributions to scientific programs in bone marrow transplantation, leukemia, lymphoma, breast cancer, and symptom management have distinguished the Tufts-New England Medical Center's contributions to ECOG over these years. ? ? This grant requests support for Tufts-NEMC to continue its mission as a main ECOG institution, supporting NCI sponsored cancer clinical trials throughout New England. The grant will support scientific activity, growth in accrual, and importantly, continued mentoring of promising junior investigators. The Tufts-NEMC ECOG network includes a large network of hospitals in 3 New England States: Massachusetts, Connecticut, and Maine, in addition to obligations in Rhode Island. We request salary support for the Principal Investigator, scientific study chairs, data managers and coordinators to support these efforts. Increasingly, network support requires emphasis on regulatory compliance, auditing and implementation of electronic tools for registration and data submission. Funds will support the Principal Investigator, study chairs, data management, and travel to and from ECOG meetings and shall be used to enhance electronic communications and data management across a broad geographic region. New affiliate sites have successfully opened since the last grant, and improving accrual and implementation of standardized network data monitoring are important goals for this next 5 year grant. A new research program in symptom management will be initiated. Mentoring successful junior scientists and introduction of postdoctoral fellows and junior faculty to ECOG to increase accrual and related scientific activities are important aspects of this program for the next 5 years. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA007190-41
Application #
6775316
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1982-12-01
Project End
2007-04-30
Budget Start
2004-07-09
Budget End
2005-04-30
Support Year
41
Fiscal Year
2004
Total Cost
$332,567
Indirect Cost
Name
Tufts University
Department
Type
DUNS #
079532263
City
Boston
State
MA
Country
United States
Zip Code
02111
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Ganz, Patricia A; Land, Stephanie R; Geyer Jr, Charles E et al. (2011) Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 29:1110-6
Landry, Jerome; Catalano, Paul J; Staley, Charles et al. (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101:587-92
Swain, Sandra M; Jeong, Jong-Hyeon; Geyer Jr, Charles E et al. (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053-65
Hughes, Lorie L; Wang, Molin; Page, David L et al. (2009) Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:5319-24
Horn, Leora; Dahlberg, Suzanne E; Sandler, Alan B et al. (2009) Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 27:6006-11
Greenberg, Peter L; Sun, Zhuoxin; Miller, Kenneth B et al. (2009) Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 114:2393-400
Souphron, Judith; Waddell, M Brett; Paydar, Amir et al. (2008) Structural dissection of a gating mechanism preventing misactivation of ubiquitin by NEDD8's E1. Biochemistry 47:8961-9
Burtness, Barbara; Goldwasser, Meredith A; Flood, William et al. (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646-54

Showing the most recent 10 out of 30 publications